Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study
Author(s) -
M.A. Valantin,
Sidonie Lambert-Niclot,
Philippe Flandre,
Laurence MorandJoubert,
André Cabie,
J.L. Meynard,
Diane Ponscarme,
F. Ajana,
Laurence Slama,
Angélique Curjol,
Lise Cuzin,
L Schneider,
A M Taburet,
AnneGeneviève Marcelin,
Christine Katlama,
Claudine Duvivier,
Vincent Cálvez,
Gilles Peytavin,
S. Kolta,
Dominique Costagliola,
Michèle Genin,
M.- J. Commoy,
Marianne L’Hénaff,
Arnaud Chéret,
François Raffi,
Rodolphe Garaffo,
Diane Descamps,
Geneviève Chêne
Publication year - 2011
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkr504
Subject(s) - darunavir , ritonavir , medicine , human immunodeficiency virus (hiv) , virology , term (time) , viral load , antiretroviral therapy , physics , quantum mechanics
Long-term results at week 96 are needed to evaluate the capacity of the darunavir/ritonavir monotherapy strategy to maintain a sustained control of the HIV-1 viral load.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom